Caldera Freddy, Knutson Keith L, Saha Sumona, Wald Arnold, Phan Hiep S, Chun Kelly, Grimes Ian, Lutz Megan, Hayney Mary S, Farraye Francis A
Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
Department of Immunology, Mayo Clinic Jacksonville, Florida, USA.
Am J Gastroenterol. 2022 Jan 1;117(1):176-179. doi: 10.14309/ajg.0000000000001570.
Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs).
We performed a prospective study to evaluate humoral immunogenicity among patients with IBD and HCs after completion of mRNA COVID-19 vaccines.
One hundred twenty-two patients with IBD and 60 HCs were enrolled. All HCs and 97% of patients with IBD developed antibodies. Antibody concentrations were lower in patients with IBD compared with those in HCs (median 31 vs 118 μg/mL; P < 0.001). Those who received the mRNA-1273 (Moderna) COVID-19 (median 38; interquartile range [IQR] 24-75 vs μg/mL) had higher antibody concentrations compared with those who received the Pfizer-BNT vaccine series (median 22; IQR 11-42 μg/mL; P < 0.001). Patients on immune-modifying therapy (median 26; IQR 13-50 μg/mL) had lower antibody concentrations compared with those who were on no treatment, aminosalicylates, or vedolizumab (median 59; IQR 31-75 μg/mL; P = 0.003).
Almost all patients with IBD in our study mounted an antibody response. Future studies are needed in evaluating sustained humoral immunity and the impact of booster dosing in patients with IBD.
接受免疫调节治疗的炎症性肠病（IBD）患者对某些疫苗的反应可能较低。我们研究的目的是评估2019冠状病毒病（COVID-19）mRNA疫苗在IBD患者和健康对照（HC）中的体液免疫原性。
我们进行了一项前瞻性研究，以评估IBD患者和HC在完成COVID-19 mRNA疫苗接种后的体液免疫原性。
纳入了122例IBD患者和60例HC。所有HC和97%的IBD患者产生了抗体。IBD患者的抗体浓度低于HC（中位数31 vs 118 μg/mL；P < 0.001）。接受mRNA-1273（Moderna）COVID-19疫苗的患者（中位数38；四分位间距[IQR] 24-75 μg/mL）的抗体浓度高于接受辉瑞-BNT疫苗系列的患者（中位数22；IQR 11-42 μg/mL；P < 0.001）。接受免疫调节治疗的患者（中位数26；IQR 13-50 μg/mL）的抗体浓度低于未接受治疗、使用氨基水杨酸类药物或维多珠单抗的患者（中位数59；IQR 31-75 μg/mL；P = 0.003）。
我们研究中几乎所有IBD患者都产生了抗体反应。未来需要开展研究评估IBD患者的持续体液免疫以及加强剂量的影响。
